{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:30:23Z","timestamp":1786516223154,"version":"build-2736575974"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have transformed the treatment of EGFR-mutant non\u2013small-cell lung cancer (NSCLC), significantly improving survival outcomes and quality of life compared with conventional chemotherapy. However, inhibition of EGFR signaling, a key regulator of epidermal homeostasis, frequently results in dermatologic adverse drug reactions (ADRs), which may compromise treatment adherence and negatively affect patient well-being. This study aimed to characterize the real-world reporting patterns of cutaneous ADRs associated with five EGFR-TKIs using large-scale pharmacovigilance databases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective pharmacovigilance analysis was performed using the World Health Organization VigiAccess\u2122 database. Reports associated with gefitinib, erlotinib, afatinib, osimertinib, and lazertinib were extracted and evaluated. Dermatologic ADRs included disorders of the skin, subcutaneous tissue, hair, nails, and mucosa. Reporting frequencies and disproportionality analyses were conducted to compare dermatologic toxicity profiles across agents. To validate the findings and assess reproducibility, an independent analysis was additionally performed using the European Medicines Agency (EMA) EudraVigilance database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 96,386 ADR reports were identified, of which 25,383 (29.7%) involved dermatologic manifestations. Rash and pruritus were the most frequently reported cutaneous ADRs across all EGFR-TKIs, although their proportional distribution differed between agents. Erlotinib and afatinib demonstrated the highest proportions of dermatologic reports (30.8% and 43.0%, respectively), whereas osimertinib exhibited a lower relative frequency (11.6%) but a greater proportion of nail and hair disorders within the dermatologic category. Lazertinib displayed a distinct reporting pattern characterized by frequent rash and pruritus signals, while maintaining an overall dermatologic profile consistent with the class effect of EGFR inhibition. Disproportionality analyses revealed statistically significant differences in reporting patterns among individual EGFR-TKIs. Comparable trends were observed in the EudraVigilance database, supporting the reproducibility and external validity of the identified safety signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Large-scale pharmacovigilance data demonstrate that although dermatologic toxicity represents a class effect of EGFR inhibition, substantial differences exist in the spectrum and relative frequency of cutaneous ADRs among individual EGFR-TKIs. Cross-validation using independent pharmacovigilance systems strengthens the reliability of these findings and underscores the importance of agent-specific toxicity surveillance. These results support proactive multidisciplinary management strategies aimed at minimizing treatment interruptions, optimizing therapeutic adherence, and improving patient-centered care in individuals with EGFR-mutant NSCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1789598","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:54:38Z","timestamp":1786514078000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Global pharmacovigilance analysis of dermatologic toxicity in EGFR-TKI\u2013treated NSCLC: a cross-database real-world study"],"prefix":"10.3389","volume":"17","author":[{"given":"Natalia","family":"Sauer","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Pharmacy, Wroclaw Medical University","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Giedziun","sequence":"additional","affiliation":[{"name":"Department of Artificial Intelligence, Wroclaw University of Science and Technology","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Calik","sequence":"additional","affiliation":[{"name":"Old Town Clinic","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wiela-Hoje\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Pharmacy, Wroclaw Medical University","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e70028","DOI":"10.1002\/der2.70028","article-title":"The role of keratinocytes in skin health and disease","volume":"6","author":"Al-Dhubaibi","year":"2025","journal-title":"Dermatol. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1177\/1078155220930285","article-title":"A review of osimertinib in NSCLC and pharmacist role in NSCLC patient care","volume":"26","author":"Al-Quteimat","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3390\/ph17060683","article-title":"Pharmacovigilance practices by healthcare providers in oncology: a cross-sectional study","volume":"17","author":"Alkofide","year":"2024","journal-title":"Pharm. Basel, Switz."},{"key":"B4","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1007\/s11096-018-0706-9","article-title":"Pharmacovigilance in oncology","volume":"40","author":"Baldo","year":"2018","journal-title":"Int. Journal Clinical Pharmacy"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1177\/1078155218786048","article-title":"The role of the pharmacist in the multidisciplinary approach to the prevention and resolution of drug-related problems in cancer chemotherapy","volume":"25","author":"Bo\u015fnak","year":"2018","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B6","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3892\/or.2020.7911","article-title":"Potentially life-threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors","volume":"45","author":"Coleman","year":"2021","journal-title":"Oncol. Reports"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"B8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jtho.2016.11.2236","article-title":"Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-Mutated non-small cell lung cancer","volume":"12","author":"Ding","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"100115","DOI":"10.1016\/j.apjon.2022.100115","article-title":"Experience of patients with lung cancer and with targeted therapy-related skin adverse drug reactions: a qualitative study","volume":"9","author":"Du","year":"2022","journal-title":"Asia-Pacific Journal Oncology Nursing"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e1004969","DOI":"10.1080\/23723556.2015.1004969","article-title":"Mechanisms underlying skin disorders induced by EGFR inhibitors","volume":"2","author":"Holcmann","year":"2015","journal-title":"Mol. Cell. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"9211","DOI":"10.1007\/s00520-022-07347-1","article-title":"Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors","volume":"30","author":"Hsu","year":"2022","journal-title":"Support Care Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5014","DOI":"10.1200\/JCO.23.00515","article-title":"Lazertinib versus gefitinib as first-line treatment in patients with EGFR-Mutated advanced Non\u2013Small-Cell lung cancer: results from LASER301","volume":"41","author":"Hwang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.clcc.2020.01.001","article-title":"Management of EGFR inhibitor-induced skin toxicity and factors impacting patients' adherence to skin toxicity treatment: health care provider and patient surveys in European oncology centers","volume":"19","author":"Kafatos","year":"2020","journal-title":"Clin. Colorectal Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.21037\/tcr.2018.10.06","article-title":"EGFR first- and second-generation TKIs-there is still place for them in EGFR-Mutant NSCLC patients","volume":"8","author":"Karachaliou","year":"2019","journal-title":"Transl. Cancer Research"},{"key":"B15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/jjco\/hyv207","article-title":"Skin problems and EGFR-Tyrosine kinase inhibitor","volume":"46","author":"Kozuki","year":"2016","journal-title":"Jpn. Journal Clinical Oncology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support. Care Cancer Official Journal Multinatl. Assoc. Support. Care Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1586\/era.13.30","article-title":"Dermatologic adverse events associated with afatinib: an oral ErbB family blocker","volume":"13","author":"Lacouture","year":"2013","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3390\/pharmaceutics15061604","article-title":"The resistance to EGFR-TKIs in non-small cell lung cancer: from molecular mechanisms to clinical application of new therapeutic strategies","volume":"15","author":"Laface","year":"2023","journal-title":"Pharmaceutics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"adv40555","DOI":"10.2340\/actadv.v104.40555","article-title":"Skin toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitors and their influence on treatment adjustments in lung cancer patients","volume":"104","author":"Lee","year":"2024","journal-title":"Acta Derm. Venereol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"804212","DOI":"10.3389\/fonc.2022.804212","article-title":"Mechanism of lethal skin toxicities induced by epidermal growth factor receptor inhibitors and related treatment strategies","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12964-023-01082-8","article-title":"Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer","volume":"21","author":"Li","year":"2023","journal-title":"Cell Commun. Signal"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6579","DOI":"10.21037\/jtd-24-682","article-title":"Risk of treatment-related toxicity from EGFR tyrosine kinase inhibitors: a systematic review and network meta-analysis of randomized clinical trials in EGFR-Mutant non-small cell lung cancer","volume":"16","author":"Li","year":"2024","journal-title":"J. Thorac. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"17588359241289648","DOI":"10.1177\/17588359241289648","article-title":"Expert consensus on the use of third-generation EGFR-TKIs in EGFR-Mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-\/second-generation EGFR-TKIs","volume":"16","author":"Ma","year":"2024","journal-title":"Ther. Advances Medical Oncology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1358\/dot.2016.52.10.2541343","article-title":"Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations","volume":"52","author":"McCoach","year":"2016","journal-title":"Drugs Today (Barcelona, Spain 1998)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3747\/co.22.2430","article-title":"Management of egfr tki-induced dermatologic adverse events","volume":"22","author":"Melosky","year":"2015","journal-title":"Curr. Oncol. Tor. Ont."},{"key":"B25","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1056\/NEJMc1913972","article-title":"Myocardial viability and long-term outcomes in ischemic cardiomyopathy","volume":"381","author":"Napp","year":"2019","journal-title":"N. Engl. Journal Medicine"},{"key":"B28","volume-title":"Non-Small Cell Lung Cancer","year":"2026"},{"key":"B29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.5603\/OCP.2016.0004","article-title":"Side effects of tyrosine kinase Inhibitors\u2014Management guidelines","volume":"12","author":"P\u0142u\u017ca\u0144ski","year":"2016","journal-title":"Oncol. Clin. Pract."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1200\/JCO-25-02822","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, 2026","volume":"44","author":"Puri","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.abd.2022.10.004","article-title":"EGFR inhibitors: clinical aspects, risk factors and biomarkers for acneiform eruptions and other mucosal and cutaneous adverse effects","volume":"98","author":"Recuero","year":"2023","journal-title":"An. Bras. Dermatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"8633","DOI":"10.1200\/JCO.2025.43.16_suppl.8633","article-title":"Hypothesis-generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations: heat on beat randomized phase II study","volume":"43","author":"Seki","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/cells13010047","article-title":"Targeted inhibitors of EGFR: structure, biology, biomarkers, and clinical applications","volume":"13","author":"Shaban","year":"2024","journal-title":"Cells"},{"key":"B35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced Non\u2013Small-Cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e20510","DOI":"10.1097\/MD.0000000000020510","article-title":"Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: an observational study","volume":"99","author":"Tseng","year":"2020","journal-title":"Medicine"},{"key":"B38","doi-asserted-by":"publisher","first-page":"6535","DOI":"10.2147\/OTT.S198945","article-title":"Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer","volume":"12","author":"Wang","year":"2019","journal-title":"OncoTargets Therapy"},{"key":"B39","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for osimertinib","volume":"12","author":"Yin","year":"2022","journal-title":"Sci. Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/jamadermatol.2020.1795","article-title":"Evaluation of a comprehensive skin toxicity program for patients treated with epidermal growth factor receptor inhibitors at a cancer treatment center","volume":"156","author":"Yu","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3892\/ol.2012.904","article-title":"Hand-foot syndrome in a patient with metastatic lung adenocarcinoma induced by high-dose icotinib: a case report and review of the literature","volume":"4","author":"Zheng","year":"2012","journal-title":"Oncol. Letters"},{"key":"B43","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-Mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1789598\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:54:40Z","timestamp":1786514080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1789598\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":43,"alternative-id":["10.3389\/fphar.2026.1789598"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1789598","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1789598"}}